---
document_datetime: 2025-12-21 12:05:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/opsumit.html
document_name: opsumit.html
version: success
processing_time: 0.1410534
conversion_datetime: 2025-12-24 06:42:29.447402
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Opsumit

[RSS](/en/individual-human-medicine.xml/66427)

##### Authorised

This medicine is authorised for use in the European Union

macitentan Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Opsumit](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-82185)
- [More information on Opsumit](#more-information-on-opsumit-64119)
- [More information on Opsumit](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Opsumit is a medicine used for the long-term treatment of pulmonary arterial hypertension (PAH), a condition in which there is abnormally high blood pressure in the arteries of the lungs, causing symptoms such as breathlessness and fatigue.

Opsumit is used for adults, adolescents and children aged 2 years and older in whom PAH comes with moderate or marked limitations in physical activity (corresponding to WHO functional class II or III, respectively). Opsumit can be used alone or in combination with other PAH medicines.

Opsumit contains the active substance macitentan.

Expand section

Collapse section

## How is Opsumit used?

Opsumit can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in treating PAH. The medicine is available as tablets to be taken once a day. For children, Opsumit is also available as dispersible tablets.

For more information about using Opsumit, see the package leaflet or contact your doctor or pharmacist.

## How does Opsumit work?

In PAH there is severe narrowing of the small blood vessels (arterioles) in the lungs. Because more pressure is needed to force blood through these narrowed vessels, this leads to high blood pressure in the arteries to the lungs.

The active substance in Opsumit, macitentan, works by blocking endothelin receptors. These are part of a natural mechanism in the body that can cause the small blood vessels to narrow. In patients with PAH, this mechanism is overactive and, by blocking these receptors, macitentan helps widen the arterioles in the lungs and thereby bring down the blood pressure.

## What benefits of Opsumit have been shown in studies?

In a main study involving 742 adults with PAH, Opsumit was shown to reduce the risk of PAH symptoms worsening. Patients in the study received either Opsumit or placebo (a dummy treatment) in addition to other PAH treatments for an average of 2 years. Around 37% of patients taking placebo had a worsening of their PAH symptoms compared with 24% of those who took Opsumit.

In another main study, 148 adolescents and children over 2 years of age with PAH were given Opsumit or standard treatment for an average of about 3 years. During the study, about 29% of patients given Opsumit and 32% of patients given standard treatment experienced a worsening of their disease. Data also showed that children and adolescents given Opsumit were able to achieve levels of the medicine in their blood comparable to those seen in adults.

## What are the risks associated with Opsumit?

For the full list of side effects and restrictions with Opsumit, see the package leaflet.

The most common side effects with Opsumit in adults and adolescents (which may affect more than 1 in 10 people) include nasopharyngitis (inflammation of the nose and throat), anaemia (low levels of red blood cells) and headache. Side effects in children and adolescents are comparable with those seen in adults, but also include upper respiratory tract (nose and throat) infection, rhinitis (stuffy and runny nose) and gastroenteritis (diarrhoea and vomiting).

In animal studies, Opsumit was shown to have an adverse effect on the development of embryos. Opsumit must therefore not be used in pregnant or breastfeeding women or in women who could become pregnant and who are not using reliable contraception. Women should also not become pregnant in the first month after stopping treatment.

Opsumit must also not be used in patients with severe reduction in liver function or high levels of liver enzymes in the blood.

## Why is Opsumit authorised in the EU?

The European Medicines Agency decided that Opsumit's benefits are greater than its risks and it can be authorised for use in the EU. In adults, Opsumit has been shown to be effective in reducing illness or deaths due to PAH. In adolescents and children, study data do not allow firm conclusions to be drawn on the benefits of Opsumit on disease progression; however, Opsumit is expected to work in the same way as it does in adults as supported by data on how the medicine behaves in the body. The side effects reported are similar to those reported with other medicines of its class and are considered to be manageable. However, Opsumit must never be used in pregnant women or women who could become pregnant and are not using reliable contraception.

## What measures are being taken to ensure the safe and effective use of Opsumit?

The company that markets Opsumit has developed educational material for patients and healthcare professionals with information on the precautions to be taken when using Opsumit. Patients' reminder cards will include a warning that the medicine must never be used in pregnant women and that women who could become pregnant must be using reliable contraception and should undergo monthly pregnancy tests.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Opsumit have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Opsumit are continuously monitored. Side effects reported with Opsumit are carefully evaluated and any necessary action taken to protect patients.

## Other information about Opsumit

Opsumit received a marketing authorisation valid throughout the EU on 20 December 2013.

Opsumit : EPAR - Medicine overview

Reference Number: EMA/442649/2024

English (EN) (117.6 KB - PDF)

**First published:** 07/02/2014

**Last updated:** 26/11/2024

[View](/en/documents/overview/opsumit-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-609)

български (BG) (135.14 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/bg/documents/overview/opsumit-epar-medicine-overview_bg.pdf)

español (ES) (109.45 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/es/documents/overview/opsumit-epar-medicine-overview_es.pdf)

čeština (CS) (133.49 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/cs/documents/overview/opsumit-epar-medicine-overview_cs.pdf)

dansk (DA) (109.93 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/da/documents/overview/opsumit-epar-medicine-overview_da.pdf)

Deutsch (DE) (113.16 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/de/documents/overview/opsumit-epar-medicine-overview_de.pdf)

eesti keel (ET) (107.61 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/et/documents/overview/opsumit-epar-medicine-overview_et.pdf)

ελληνικά (EL) (132.42 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/el/documents/overview/opsumit-epar-medicine-overview_el.pdf)

français (FR) (110.38 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/fr/documents/overview/opsumit-epar-medicine-overview_fr.pdf)

hrvatski (HR) (129.52 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/hr/documents/overview/opsumit-epar-medicine-overview_hr.pdf)

italiano (IT) (108.5 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/it/documents/overview/opsumit-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (138.3 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/lv/documents/overview/opsumit-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (130.22 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/lt/documents/overview/opsumit-epar-medicine-overview_lt.pdf)

magyar (HU) (132.91 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/hu/documents/overview/opsumit-epar-medicine-overview_hu.pdf)

Malti (MT) (134.16 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/mt/documents/overview/opsumit-epar-medicine-overview_mt.pdf)

Nederlands (NL) (110.44 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/nl/documents/overview/opsumit-epar-medicine-overview_nl.pdf)

polski (PL) (135.44 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/pl/documents/overview/opsumit-epar-medicine-overview_pl.pdf)

português (PT) (110.08 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/pt/documents/overview/opsumit-epar-medicine-overview_pt.pdf)

română (RO) (128.92 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/ro/documents/overview/opsumit-epar-medicine-overview_ro.pdf)

slovenčina (SK) (132.8 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/sk/documents/overview/opsumit-epar-medicine-overview_sk.pdf)

slovenščina (SL) (130.14 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/sl/documents/overview/opsumit-epar-medicine-overview_sl.pdf)

Suomi (FI) (106.65 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/fi/documents/overview/opsumit-epar-medicine-overview_fi.pdf)

svenska (SV) (108.58 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/sv/documents/overview/opsumit-epar-medicine-overview_sv.pdf)

Opsumit : EPAR - Risk management plan

English (EN) (1.69 MB - PDF)

**First published:** 24/06/2020

**Last updated:** 26/11/2024

[View](/en/documents/rmp/opsumit-epar-risk-management-plan_en.pdf)

## Product information

Opsumit : EPAR - Product information

English (EN) (427.74 KB - PDF)

**First published:** 07/02/2014

**Last updated:** 16/12/2025

[View](/en/documents/product-information/opsumit-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-787)

български (BG) (593.61 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/bg/documents/product-information/opsumit-epar-product-information_bg.pdf)

español (ES) (601.64 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/es/documents/product-information/opsumit-epar-product-information_es.pdf)

čeština (CS) (550.84 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/cs/documents/product-information/opsumit-epar-product-information_cs.pdf)

dansk (DA) (682.61 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/da/documents/product-information/opsumit-epar-product-information_da.pdf)

Deutsch (DE) (541.97 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/de/documents/product-information/opsumit-epar-product-information_de.pdf)

eesti keel (ET) (538.57 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/et/documents/product-information/opsumit-epar-product-information_et.pdf)

ελληνικά (EL) (576.04 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/el/documents/product-information/opsumit-epar-product-information_el.pdf)

français (FR) (572.05 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/fr/documents/product-information/opsumit-epar-product-information_fr.pdf)

hrvatski (HR) (591.79 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/hr/documents/product-information/opsumit-epar-product-information_hr.pdf)

íslenska (IS) (499.53 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/is/documents/product-information/opsumit-epar-product-information_is.pdf)

italiano (IT) (557.94 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/it/documents/product-information/opsumit-epar-product-information_it.pdf)

latviešu valoda (LV) (562.92 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/lv/documents/product-information/opsumit-epar-product-information_lv.pdf)

lietuvių kalba (LT) (568.07 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/lt/documents/product-information/opsumit-epar-product-information_lt.pdf)

magyar (HU) (600.19 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/hu/documents/product-information/opsumit-epar-product-information_hu.pdf)

Malti (MT) (591.51 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/mt/documents/product-information/opsumit-epar-product-information_mt.pdf)

Nederlands (NL) (559.74 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/nl/documents/product-information/opsumit-epar-product-information_nl.pdf)

norsk (NO) (485.71 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/no/documents/product-information/opsumit-epar-product-information_no.pdf)

polski (PL) (577.65 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/pl/documents/product-information/opsumit-epar-product-information_pl.pdf)

português (PT) (555.38 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/pt/documents/product-information/opsumit-epar-product-information_pt.pdf)

română (RO) (556.88 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/ro/documents/product-information/opsumit-epar-product-information_ro.pdf)

slovenčina (SK) (565.56 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/sk/documents/product-information/opsumit-epar-product-information_sk.pdf)

slovenščina (SL) (555.84 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/sl/documents/product-information/opsumit-epar-product-information_sl.pdf)

Suomi (FI) (539.27 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/fi/documents/product-information/opsumit-epar-product-information_fi.pdf)

svenska (SV) (543.53 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

16/12/2025

[View](/sv/documents/product-information/opsumit-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000313635 16/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Opsumit : EPAR - All authorised presentations

English (EN) (23.92 KB - PDF)

**First published:** 07/02/2014

**Last updated:** 26/11/2024

[View](/en/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-492)

български (BG) (28 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/bg/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_bg.pdf)

español (ES) (23.26 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/es/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_es.pdf)

čeština (CS) (25.31 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/cs/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (32.49 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/da/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (26.2 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/de/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (25.12 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/et/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (27 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/el/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_el.pdf)

français (FR) (30.33 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/fr/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (30.63 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/hr/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (32.83 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/is/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_is.pdf)

italiano (IT) (23.73 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/it/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (32.11 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/lv/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (32.48 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/lt/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (25.79 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/hu/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (25.21 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/mt/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (29.88 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/nl/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (32.37 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/no/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_no.pdf)

polski (PL) (25.87 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/pl/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_pl.pdf)

português (PT) (23.85 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/pt/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_pt.pdf)

română (RO) (30.41 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/ro/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (33.23 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/sk/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (30.77 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/sl/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (31.8 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/fi/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (31.69 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

26/11/2024

[View](/sv/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_sv.pdf)

Opsumit : EPAR - Conditions imposed on member states for safe and effective use - Annex related to the Art. 127a

English (EN) (17.91 KB - PDF)

**First published:** 07/02/2014

**Last updated:** 07/02/2014

[View](/en/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_en.pdf)

[Other languages (24)](#file-language-dropdown-769)

български (BG) (64.61 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/bg/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_bg.pdf)

español (ES) (18.4 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/es/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_es.pdf)

čeština (CS) (66.99 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/cs/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_cs.pdf)

dansk (DA) (18.13 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/da/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_da.pdf)

Deutsch (DE) (18.37 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/de/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_de.pdf)

eesti keel (ET) (13.51 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/et/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_et.pdf)

ελληνικά (EL) (62.11 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/el/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_el.pdf)

français (FR) (18.61 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/fr/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_fr.pdf)

hrvatski (HR) (64.2 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/hr/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_hr.pdf)

íslenska (IS) (17.86 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/is/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_is.pdf)

italiano (IT) (18.06 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/it/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_it.pdf)

latviešu valoda (LV) (67.27 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/lv/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_lv.pdf)

lietuvių kalba (LT) (66.78 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/lt/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_lt.pdf)

magyar (HU) (63.98 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/hu/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_hu.pdf)

Malti (MT) (71.1 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/mt/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_mt.pdf)

Nederlands (NL) (17.83 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/nl/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_nl.pdf)

norsk (NO) (17.65 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/no/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_no.pdf)

polski (PL) (66.72 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/pl/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_pl.pdf)

português (PT) (18.6 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/pt/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_pt.pdf)

română (RO) (67.37 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/ro/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_ro.pdf)

slovenčina (SK) (67.97 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/sk/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_sk.pdf)

slovenščina (SL) (63.2 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/sl/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_sl.pdf)

Suomi (FI) (18.27 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/fi/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_fi.pdf)

svenska (SV) (17.76 KB - PDF)

**First published:**

07/02/2014

**Last updated:**

07/02/2014

[View](/sv/documents/conditions-member-states/opsumit-epar-conditions-imposed-member-states-safe-and-effective-use-annex-related-art-127a_sv.pdf)

## Product details

Name of medicine Opsumit Active substance macitentan International non-proprietary name (INN) or common name macitentan Therapeutic area (MeSH) Hypertension, Pulmonary Anatomical therapeutic chemical (ATC) code C02KX04

### Pharmacotherapeutic group

Antihypertensives

### Therapeutic indication

Adults Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.

Paediatric population Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in paediatric patients aged less than 18 years and bodyweight ≥ 40 kg with WHO Functional Class (FC) II to III.

Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in paediatric patients aged 2 years to less than 18 years with WHO Functional Class (FC) II to III.

## Authorisation details

EMA product number EMEA/H/C/002697 Marketing authorisation holder

Janssen-Cilag International N.V.

Turnhoutseweg 30 BE-2340 Beerse Belgium

Marketing authorisation issued 20/12/2013 Revision 26

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Opsumit : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.32 KB - PDF)

**First published:** 04/04/2025

**Last updated:** 16/12/2025

[View](/en/documents/procedural-steps-after/opsumit-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Opsumit : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (236.13 KB - PDF)

**First published:** 02/10/2014

**Last updated:** 04/04/2025

[View](/en/documents/procedural-steps-after/opsumit-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Opsumit-H-C-002697-X-0051-G : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/389480/2024

English (EN) (6.9 MB - PDF)

**First published:** 26/11/2024

[View](/en/documents/variation-report/opsumit-h-c-002697-x-0051-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Opsumit (X-51-G)

Adopted

Reference Number: EMA/CHMP/326580/2024

English (EN) (154.66 KB - PDF)

**First published:** 26/07/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opsumit-x-51-g_en.pdf)

Opsumit-H-C-2697-P46-011 : EPAR - Assessment report

Adopted

Reference Number: EMA/953202/2022

English (EN) (3.75 MB - PDF)

**First published:** 22/12/2022

[View](/en/documents/variation-report/opsumit-h-c-2697-p46-011-epar-assessment-report_en.pdf)

Opsumit-H-C-2697-P46-008 : EPAR - Assessment Report

Adopted

Reference Number: EMA/687037/2018

English (EN) (931.56 KB - PDF)

**First published:** 09/10/2018

[View](/en/documents/variation-report/opsumit-h-c-2697-p46-008-epar-assessment-report_en.pdf)

Opsumit-H-C-2697-P46-006 : EPAR - Assessment Report

Reference Number: EMA/792503/2017

English (EN) (580.22 KB - PDF)

**First published:** 30/11/2017

**Last updated:** 30/11/2017

[View](/en/documents/variation-report/opsumit-h-c-2697-p46-006-epar-assessment-report_en.pdf)

Opsumit-H-C-2697-PSUV-0003 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/52026/2015

English (EN) (64.95 KB - PDF)

**First published:** 24/02/2015

**Last updated:** 24/02/2015

[View](/en/documents/scientific-conclusion/opsumit-h-c-2697-psuv-0003-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Opsumit : EPAR - Public assessment report

Adopted

Reference Number: EMA/457699/2013

English (EN) (2.89 MB - PDF)

**First published:** 07/02/2014

**Last updated:** 07/02/2014

[View](/en/documents/assessment-report/opsumit-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Opsumit

Adopted

Reference Number: EMA/CHMP/590387/2013

English (EN) (70.38 KB - PDF)

**First published:** 25/10/2013

**Last updated:** 25/10/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-opsumit_en.pdf)

#### News on Opsumit

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024) 26/07/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2019 (updated)](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-november-2019-updated) 15/11/2019

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 October 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-october-2013) 25/10/2013

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Opsumit : EPAR - Product information - tracked changes

English (EN) (286.18 KB - DOCX)

**First published:** 16/12/2025

[View](/en/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-505)

български (BG) (954 KB - DOC)

**First published:**

16/12/2025

[View](/bg/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_bg.doc)

español (ES) (351.33 KB - DOCX)

**First published:**

16/12/2025

[View](/es/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_es.docx)

čeština (CS) (931.5 KB - DOC)

**First published:**

16/12/2025

[View](/cs/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_cs.doc)

dansk (DA) (483.38 KB - DOCX)

**First published:**

16/12/2025

[View](/da/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (330.09 KB - DOCX)

**First published:**

16/12/2025

[View](/de/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (301.76 KB - DOCX)

**First published:**

16/12/2025

[View](/et/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (334.27 KB - DOCX)

**First published:**

16/12/2025

[View](/el/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_el.docx)

français (FR) (337.5 KB - DOCX)

**First published:**

16/12/2025

[View](/fr/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (310.2 KB - DOCX)

**First published:**

16/12/2025

[View](/hr/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (288.69 KB - DOCX)

**First published:**

16/12/2025

[View](/is/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_is.docx)

italiano (IT) (677 KB - DOC)

**First published:**

16/12/2025

[View](/it/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_it.doc)

latviešu valoda (LV) (517.28 KB - DOCX)

**First published:**

16/12/2025

[View](/lv/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (302.28 KB - DOCX)

**First published:**

16/12/2025

[View](/lt/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (316.56 KB - DOCX)

**First published:**

16/12/2025

[View](/hu/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (341.1 KB - DOCX)

**First published:**

16/12/2025

[View](/mt/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (867 KB - DOC)

**First published:**

16/12/2025

[View](/nl/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_nl.doc)

norsk (NO) (273.03 KB - DOCX)

**First published:**

16/12/2025

[View](/no/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_no.docx)

polski (PL) (327.96 KB - DOCX)

**First published:**

16/12/2025

[View](/pl/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_pl.docx)

português (PT) (734.5 KB - DOC)

**First published:**

16/12/2025

[View](/pt/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_pt.doc)

română (RO) (290.15 KB - DOCX)

**First published:**

16/12/2025

[View](/ro/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (855 KB - DOC)

**First published:**

16/12/2025

[View](/sk/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_sk.doc)

slovenščina (SL) (320.14 KB - DOCX)

**First published:**

16/12/2025

[View](/sl/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (302.79 KB - DOCX)

**First published:**

16/12/2025

[View](/fi/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (331.95 KB - DOCX)

**First published:**

16/12/2025

[View](/sv/documents/product-information-tracked-changes/opsumit-epar-product-information-tracked-changes_sv.docx)

#### More information on Opsumit

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-909) on 27 September 2011. Opsumit was withdrawn from the Community register of orphan medicinal products in December 2023 upon request of the marketing authorisation holder

#### More information on Opsumit

- [EMEA-001032-PIP01-10-M07 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001032-pip01-10-m07)
- [EMEA-001032-PIP02-17 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001032-pip02-17)
- [Opsumit - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/opsumit)
- [EMEA-001032-PIP03-19 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001032-pip03-19)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 16/12/2025

## Share this page

[Back to top](#main-content)